FDA grants fast track designation for Boehringer Ingelheim’s BIBW 2992 for the treatment of late stage non small cell lung cancer (NSCLC)

29.02.08 - 17:24 ... source : Boehringer Ingelheim

... 14 February 2008 For medical media, outside the US only Ingelheim/Germany, 14. February 2008 – Boehringer Ingelheim’s investigational cancer treatment BIBW 2992 has recently received a Fast Track Designation status by the FDA. Under this designation, Boehringer Ingelheim will conduct a pivotal trial programme studying BIBW 2992 in a non-small cell lung cancer (NSCLC) patient group where prior treatment with reversible EGFR inhibitors has failed. The FDA`s Fast Track Programme will facilitate the development programme and expedite the review of new treatments that demonstrate the potential to address an unmet medical need in serious or life-threatening diseases. "We are pleased that the FDA acknowledges the therapeutic potential of BIBW 2992 by granting a Fast Track Designation." stated Dr Andreas Barner, Member of the Board of ...» Next (HTML)